首发精神病治疗抵抗风险临床预测模型的开发与初步评估:精神分裂症治疗抵抗预测(SPIRIT)
研究利用英国两个首发精神病队列(GAP与AESOP-10)数据,基于惩罚逻辑回归开发并内部验证预测治疗抵抗性精神分裂症风险的模型,纳入1081例患者,模型C统计量为0.727(95%CI 0.723-0.732),乐观校正后为0.687,校准良好;作者结论认为该模型预测指标尚可,需外部验证后通过协同设计方法支持在早期干预服务中实施。
要点
- 模型纳入7个首发精神病临床常规评估因素,预测1081例患者治疗抵抗风险,C统计量0.727(95%CI 0.723-0.732)。
- 乐观校正后C统计量为0.687,校准良好(期望/观察比值0.999;校准截距0.000584)。
- 作者结论:模型预测指标尚可,需外部验证及协同设计以支持在早期干预服务中实施。
核心结论
- 作者开发并内部验证了一个预测指标尚可的预测模型,临床医生、患者和照护者参与了开发过程。
- 作者认为需要对该工具进行外部验证,随后通过协同设计方法支持在早期干预服务中实施。
研究设计与样本
- 研究使用英国两个首发精神病队列(GAP和AESOP-10)的数据开发并内部验证预后模型,以支持在首发精神病诊断后不久识别治疗抵抗高风险患者。
- 模型基于惩罚逻辑回归开发,使用社会人口学和临床预测因素,缺失数据采用多重插补处理。
- 通过自举法进行内部验证,获得模型性能的乐观校正估计;与临床医生进行访谈和焦点小组,以确定临床相关风险阈值并了解模型的可接受性和感知效用。
主要发现
- 预测模型纳入7个在首发精神病患者临床实践中主要评估的因素。
- 模型对1081例患者的治疗抵抗预测具有合理准确性:收缩前C统计量为0.727(95%CI 0.723-0.732),乐观校正后为0.687。
- 乐观校正后校准良好:期望/观察比值为0.999;校准截距为0.000584。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出需要对该工具进行外部验证,随后通过协同设计方法支持在早期干预服务中实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A clinical tool to estimate the risk of treatment-resistant schizophrenia (TRS) in people with first-episode psychosis (FEP) would inform early detection of TRS and overcome the delay of up to 5 years in starting TRS medication. AIMS: To develop and evaluate a model that could predict the risk of TRS in routine clinical practice. METHOD: We used data from two UK-based FEP cohorts (GAP and AESOP-10) to develop and internally validate a prognostic model that supports identification of patients at high-risk of TRS soon after FEP diagnosis. Using sociodemographic and clinical predictors, a model for predicting risk of TRS was developed based on penalised logistic regression, with missing data handled using multiple imputation. Internal validation was undertaken via bootstrapping, obtaining optimism-adjusted estimates of the model's performance. Interviews and focus groups with clinicians were conducted to establish clinically relevant risk thresholds and understand the acceptability and perceived utility of the model. RESULTS: We included seven factors in the prediction model that are predominantly assessed in clinical practice in patients with FEP. The model predicted treatment resistance among the 1081 patients with reasonable accuracy; the model's C-statistic was 0.727 (95% CI 0.723-0.732) prior to shrinkage and 0.687 after adjustment for optimism. Calibration was good (expected/observed ratio: 0.999; calibration-in-the-large: 0.000584) after adjustment for optimism. CONCLUSIONS: We developed and internally validated a prediction model with reasonably good predictive metrics. Clinicians, patients and carers were involved in the development process. External validation of the tool is needed followed by co-design methodology to support implementation in early intervention services.
引用
- Farooq S, Hattle M, Kingstone T, et al. Development and initial evaluation of a clinical prediction model for risk of treatment resistance in first-episode psychosis: Schizophrenia Prediction of Resistance to Treatment (SPIRIT). Br J Psychiatry. 2024. PMID: 39101211. doi:10.1192/bjp.2024.101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。